CORRECTING and REPLACING BT Brands Reports First Quarter 2025 Results
MINNETONKA, Minn.--(BUSINESS WIRE)--May 15, 2025--
Please replace the release with the following corrected version to replace the second bullet point and the Condensed Consolidated Balance Sheets table.
The updated release reads:
BT BRANDS REPORTS FIRST QUARTER 2025 RESULTS
BT Brands, Inc. (Nasdaq: BTBD and BTBDW), today reported its financial results for the first quarter, the thirteen weeks ending March 30, 2025.
Including our 41.7% ownership of Bagger Dave's Burger Tavern with five locations (OTCMarkets: BDVB), BT Brands currently operates a total of fifteen restaurants comprising the following:
Highlights and recent activities include:
Gary Copperud, the Company's Chief Executive Officer, said, 'The first quarter is typically slower for our Burger Time and Pie in the Sky businesses; that said, we were pleased to see improvement in our operating performance during the first quarter of 2025 reflecting a number of steps to reduce costs and improve performance in all of our businesses including our decision to close two underperforming locations. As we look forward to the balance of 2025, we are focused on continuing our efforts to improve restaurant profitability. Kenneth Brimmer, CFO, added that while we are not giving specific earnings guidance for the year, our current plan shows a return to overall profitability for fiscal 2025.
Fiscal 2025 Outlook: Because of the uncertain nature of restaurant performance and the evolving character of our Company and because of continuing uncertainty surrounding the overall economy as consumers have become more price sensitive, impacts of supply chain constraints, and inflationary pressures relating to many aspects of our business, the Company is not at this point, providing a financial forecast for fiscal 2025.
About BT Brands Inc.: BT Brands, Inc. (BTBD and BTBDW) owns and operates a fast-food restaurant chain called Burger Time in North Dakota, South Dakota and Minnesota. In addition, the Company owns the Pie In The Sky Coffee and Bakery in Woods Hole, Massachusetts, Florida, Keegan's Seafood Grille near Clearwater, Florida and Schnitzel Haus in Hobe Sound, Florida.
Cautionary Note Regarding Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding guidance relating to net income and net income per share, expected operating results, such as revenue growth and earnings, and anticipated capital expenditures for fiscal 2025.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FINANCIAL RESULTS FOLLOW:
Category: Financial Category
View source version on businesswire.com:https://www.businesswire.com/news/home/20250514994686/en/
CONTACT: Contact for Further Information:
Kenneth Brimmer 612-229-8811
KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA
INDUSTRY KEYWORD: RETAIL RESTAURANT/BAR FOOD/BEVERAGE
SOURCE: BT Brands, Inc.
Copyright Business Wire 2025.
PUB: 05/15/2025 07:46 AM/DISC: 05/15/2025 07:46 AM
http://www.businesswire.com/news/home/20250514994686/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Okta, Inc. (OKTA) Is A 'Remarkable Company,' Says Jim Cramer
We recently published a list of . In this article, we are going to take a look at where Okta, Inc. (NASDAQ:OKTA) stands against other stocks that Jim Cramer discussed. Okta, Inc. (NASDAQ:OKTA) is a cybersecurity company whose shares are up 32% year-to-date despite a 16% drop in May. The firm is a cybersecurity company that allows businesses and organizations to protect their infrastructure by allowing only authorized users to access them. Okta, Inc. (NASDAQ:OKTA)'s shares sank in May despite the fact that the firm's 86 cents in earnings and $688 million in revenue beat analyst estimates of $680 million and 77 cents. The stock dropped as the firm maintained its guidance and warned that it could face a tricky macroeconomic outlook after President Trump's tariffs. Here is what Cramer said about Okta, Inc. (NASDAQ:OKTA): "Another stock that you can buy that's not in my trust, but I love cybersecurity, is Okta. They're on tonight, Todd McKinnon, it is a remarkable company. It came back from a hack, and it's still everybody's favorite cause it's identity and that's so important as you stumble through and think that, like yesterday I got one, it looked so good. It was from the DMV, they wanted everything." Okta, Inc. (NASDAQ:OKTA)'s sector, cybersecurity, is one of Cramer's favorites due to AI-induced demand and relative insulation to tariffs. Here's what Cramer said about the firm in May: 'I think Okta is terrific. It's one of the greatest companies. I tell you, anybody who works there has a great time, and they have done remarkable things. And Todd McKinnon is terrific, and so is cybersecurity…. This one is a winner. I'm going to give you a twofer… CrowdStrike and Palo Alto Networks, they're all terrific.' Overall, OKTA ranks 1st on our list of stocks that Jim Cramer discussed. While we acknowledge the potential of OKTA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Curaleaf Reports on Voting Results from the 2025 Annual General Meeting of Shareholders
STAMFORD, Conn., June 13, 2025 /PRNewswire/ -- The annual general meeting of shareholders of Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, was held today via live webcast online (the "Meeting"). Each of the matters voted upon at the Meeting is discussed in detail in the Company's management information circular dated April 29, 2025 (the "Circular"), which can be found under the Company's profile on SEDAR+ ( and on EDGAR ( The total number of votes cast by the shareholders in person or represented by proxy at the Meeting was 1,722,745,691 votes (with each subordinate voting share entitling the holder thereof to one (1) vote, and each multiple voting share entitling the holder thereof to fifteen (15) votes). The voting results in relation to the election of directors were as follows:Percentage of Votes Name of Director For (%) Withheld (%) Michelle Bodner 99.93 0.07 Karl Johansson 98.91 1.19 Boris Jordan 97.92 2.08 Mitchell Kahn 97.92 2.08 Joseph Lusardi 97.98 2.02 Shasheen Shah 99.92 0.08 In addition, the number of directors of the Company was also set by the shareholders of Curaleaf at ten (10) directors, and the resolution with respect to the reappointment of PKF O'Connor Davies, LLP as the Company's auditor put before the shareholders for consideration and approval at the Meeting, as described in the Circular, was duly approved by the requisite number of votes. The Company has filed a report of voting results on all resolutions voted on at the Meeting under its profile on and on About Curaleaf HoldingsCuraleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Anthem and The Hemp Company provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit Investor Contact Curaleaf Holdings, Lyon, Chief Investment OfficerIR@ Media Contact Curaleaf Holdings, Rahmil, VP Public Relationsmedia@ View original content to download multimedia: SOURCE Curaleaf Holdings, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
FDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17 Agency indicates anticipated decision within four weeks CAMBRIDGE, Mass. & SALISBURY, England, June 13, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company's investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the Company believes the only remaining item under FDA review is the finalization of the labelling. "We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks," said Ben Palleiko, CEO of KalVista. "At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering." About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older and are investigating its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View source version on Contacts Ryan BakerHead, Investor Relations(617) Molly CameronDirector, Corporate Communications(978) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
